Advanced searches left 3/3

Everolimus - PubMed

Summarized by Plex Scholar
Last Updated: 07 September 2022

* If you want to update the article please login/register

Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.

Neuroendocrine liver metastases is one of the poorest prognostic factors in patients with pancreatic neuroendocrine neoplasms, and surgical removal of neuroendocrine liver metastases is the only curable therapy. However, two neuroendocrine liver metastases developed twice after more than five years of recurrence-free life. Even after 5 years of recurrence-free survival, patients with pancreatic neuroendocrine neoplasms have a likelihood of recurrence.

Source link: https://doi.org/10.1007/s12328-022-01689-3


Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics.

The study included Japanese post-liver transplant patients whose blood everolimus concentrations were measured between March 2018 and December 2020 in this research. Individual everolimus pharmacokinetic parameters determined by the post-hoc Bayesian study using the current model were compared to the tacrolimus dose per trough concentration ratio in each patient. The estimated glomerular filtration rate, concomitant use of fluconazole, sex, as well as the total daily dose of everolimus were all significant factors, impacting Everolimus clearance. The estimated individual apparent clearance of everolimus by the post-hoc Bayesian study was marginally related to each patient's D/C ratio. In conclusion, a population pharmacokinetic review identified several key covariates for everolimus pharmacokinetics in liver transplant patients. Everolimus pharmacokinetics is moderately related to tacrolimus pharmacokinetics, and could be extrapolated from adult to pediatric patients by body size correction, except for infants.

Source link: https://doi.org/10.1111/cts.13389


Tip-concentrated microneedle patch delivering everolimus for therapy of multiple sclerosis.

Multiple sclerosis is a chronic progressive demyelinating disease of the central nervous system. Multiple sclerosis systemic drug therapy for multiple sclerosis has limited success and serious side effects at present. The invasive encephalomyelitis model was used to evaluate the therapeutic effect of everolimus-loaded microneedles, which was later confirmed with neurological function tests and spinal cord histopathological findings. The tip-concentrated microneedle patch provided an efficient, safe, and simple way to deliver everolimus transdermal, bringing forth a new treatment for multiple sclerosis.

Source link: https://doi.org/10.1016/j.bioadv.2022.212729


Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients.

Regular adjustment of the dose to the appropriate level is required for the administration of immunosuppressors in solid organ transplantation. By the introduction of sotorasib, which is used for metastatic pulmonary adenocarcinoma, a 72-year-old lung transplanted man who was treated with tacrolimus and everolimus for the long run, had his residual immunosuppressor levels unbalanced.

Source link: https://doi.org/10.1016/j.trim.2022.101678

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions